CTLA4 and hepatocellular carcinoma: In some trials, positive clinical results have been observed in advanced HCC patients who received cytotoxic T-lymphocyte-associated protein 4 (CTLA4) blockade (Tremelimumab) combined with RFA, accompanied by remarkably reduced HCV viral load.